The therapeutic potential of purified cannabidiol

[1]  B. Gidal,et al.  Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy , 2023, Epilepsy & Behavior.

[2]  F. Guimarães,et al.  Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022) , 2022, Pharmaceutics.

[3]  G. Eglit,et al.  A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge. , 2022, Psychopharmacology.

[4]  T. Lovick,et al.  Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze , 2022, Journal of psychopharmacology.

[5]  F. Guimarães,et al.  Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic , 2022, Frontiers in Pharmacology.

[6]  W. Bernardo,et al.  Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex , 2022, Revista da Associacao Medica Brasileira.

[7]  J. Crippa,et al.  Cannabidiol enhances the antinociceptive effects of morphine and attenuates opioid-induced tolerance in the chronic constriction injury model , 2022, Behavioural Brain Research.

[8]  S. Dalton,et al.  Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy , 2022, Supportive Care in Cancer.

[9]  C. Davey,et al.  Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial. , 2022, The Journal of clinical psychiatry.

[10]  F. Guimarães,et al.  Cannabidiol for the treatment of autism spectrum disorder: hope or hype? , 2022, Psychopharmacology.

[11]  J. Schreiber,et al.  Variability in Serum Concentrations and Clinical Response in Artisanal Versus Pharmaceutical Cannabidiol Treatment of Pediatric Pharmacoresistant Epilepsy. , 2022, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[12]  J. Božić,et al.  Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study , 2022, Journal of personalized medicine.

[13]  A. Zuardi,et al.  The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. , 2022, Cannabis and cannabinoid research.

[14]  B. DeGeorge,et al.  A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. , 2022, The Journal of hand surgery.

[15]  G. Cleirec,et al.  Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap , 2022, Frontiers in Psychiatry.

[16]  A. V. van Balkom,et al.  Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial , 2022, European Neuropsychopharmacology.

[17]  W. Harmsen,et al.  Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial , 2022, The American journal of gastroenterology.

[18]  I. McGregor,et al.  Cannabinoids, insomnia, and other sleep disorders. , 2022, Chest.

[19]  J. Billieux,et al.  Cannabidiol in the context of substance use disorder treatment: A systematic review. , 2022, Addictive behaviors.

[20]  N. Wu,et al.  Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice , 2022, Psychopharmacology.

[21]  F. Guimarães,et al.  The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event , 2022, Revista brasileira de psiquiatria.

[22]  F. Guimarães,et al.  Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder , 2022, Psychopharmacology.

[23]  A. Schulze-Bonhage,et al.  Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study , 2021, CNS Drugs.

[24]  P. Carney,et al.  Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol , 2021, Epilepsy & Behavior.

[25]  L. Dreyer,et al.  Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. , 2021, Pain.

[26]  E. Stip,et al.  Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial , 2021, Neuropsychopharmacology.

[27]  G. Bedi,et al.  A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans , 2021, Schmerz Nachrichten.

[28]  M. Zarrindast,et al.  Cannabinoids and sleep-wake cycle: The potential role of serotonin , 2021, Behavioural Brain Research.

[29]  J. Manzanares,et al.  Cannabidiol and Sertraline Regulate Behavioral and Brain Gene Expression Alterations in an Animal Model of PTSD , 2021, Frontiers in Pharmacology.

[30]  G. Nahler,et al.  Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme. , 2021, Cancer diagnosis & prognosis.

[31]  R. Vitale,et al.  The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets , 2021, International journal of molecular sciences.

[32]  M. Hellmich,et al.  Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial , 2021, Frontiers in Pharmacology.

[33]  K. Mercer-Chalmers-Bender,et al.  Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). , 2021, Pain.

[34]  A. Wong,et al.  The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain , 2021, The Medical journal of Australia.

[35]  J. Hallak,et al.  Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder , 2021, Movement disorders : official journal of the Movement Disorder Society.

[36]  C. Hindocha,et al.  Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems , 2021, Journal of Cannabis Research.

[37]  R. Witkamp,et al.  Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. , 2021, Cannabis and cannabinoid research.

[38]  Kristen C. Cochrane-Snyman,et al.  The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men , 2021, Medicine and science in sports and exercise.

[39]  E. Stip,et al.  Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo‐controlled trial , 2021, Addiction.

[40]  C. Stevenson,et al.  Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders? , 2020, Cannabis and cannabinoid research.

[41]  J. Manzanares,et al.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders , 2020, Biomolecules.

[42]  J. Mlost,et al.  Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action , 2020, International journal of molecular sciences.

[43]  R. Laranjeira,et al.  Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study , 2020, Revista brasileira de psiquiatria.

[44]  S. Pagano,et al.  Biological effects of Cannabidiol on normal human healthy cell populations: Systematic review of the literature. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[45]  Mark Dredze,et al.  Self-reported Cannabidiol (CBD) Use for Conditions With Proven Therapies , 2020, JAMA network open.

[46]  M. Berger,et al.  Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol , 2020, BMJ Case Reports.

[47]  R. Murray,et al.  A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis , 2020, Translational Psychiatry.

[48]  Aleksandra Kicman,et al.  The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease , 2020, International journal of molecular sciences.

[49]  H. Danesh-Meyer,et al.  Cannabinoids and the eye. , 2020, Survey of ophthalmology.

[50]  G. Baio,et al.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. , 2020, The lancet. Psychiatry.

[51]  Katrina Jane Williams,et al.  A pilot randomised placebo‐controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability , 2020, British journal of clinical pharmacology.

[52]  R. Capasso,et al.  Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals? , 2020, International journal of molecular sciences.

[53]  T. England,et al.  The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial , 2020, British journal of clinical pharmacology.

[54]  C. Klier,et al.  Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression , 2020, neuropsychiatrie.

[55]  B. Arroll,et al.  Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand , 2020, BJGP open.

[56]  M. Brammer,et al.  Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis , 2020, Psychological Medicine.

[57]  P. Mcguire,et al.  Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis , 2020, Psychopharmacology.

[58]  P. C. Castro,et al.  Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease , 2020, Journal of psychopharmacology.

[59]  J. Roiser,et al.  The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study , 2019, European Neuropsychopharmacology.

[60]  P. Amminger,et al.  A Case Report of Cannabidiol Treatment of a Crohn's Disease Patient With Anxiety Disorder. , 2019, Journal of clinical psychopharmacology.

[61]  Yujiang Fang,et al.  The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. , 2019, Current pharmaceutical biotechnology.

[62]  N. Masataka.  Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders , 2019, Front. Psychol..

[63]  F. Guimarães,et al.  Cannabidiol improves metabolic dysfunction in middle-aged diabetic rats submitted to a chronic cerebral hypoperfusion. , 2019, Chemico-biological interactions.

[64]  P. McGuire,et al.  Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis , 2019, Translational Psychiatry.

[65]  Laurie E. Seltzer,et al.  Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results , 2019, Epilepsy Research.

[66]  J. Hallak,et al.  Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors , 2019, Brain Research.

[67]  Steven C. R. Williams,et al.  The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) , 2019, Journal of psychopharmacology.

[68]  Y. Hurd,et al.  Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. , 2019, The American journal of psychiatry.

[69]  C. Ortori,et al.  Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. , 2019, Inflammatory bowel diseases.

[70]  Nicole Lewis,et al.  Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series , 2019, Journal of alternative and complementary medicine.

[71]  Abraham Weizman,et al.  Cannabidiol as a suggested candidate for treatment of autism spectrum disorder , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[72]  Steven C. R. Williams,et al.  Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder , 2019, Neuropsychopharmacology.

[73]  C. Lancellotti,et al.  Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol , 2019, Front. Oncol..

[74]  F. Guimarães,et al.  Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats , 2018, Neurotoxicity Research.

[75]  Eugen Trinka,et al.  Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis , 2018, Drugs.

[76]  R. Murray,et al.  Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial , 2018, JAMA psychiatry.

[77]  F. Guimarães,et al.  Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test , 2018, Revista brasileira de psiquiatria.

[78]  A. Dalgleish,et al.  Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol , 2018, AntiCancer Research.

[79]  Jamie Corroon,et al.  A Cross-Sectional Study of Cannabidiol Users , 2018, Cannabis and cannabinoid research.

[80]  J. Hallak,et al.  Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? , 2018, Front. Pharmacol..

[81]  C. Morgan,et al.  Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal , 2018, Addiction.

[82]  F. Guimarães,et al.  No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study , 2018, Front. Pharmacol..

[83]  S. O'Sullivan,et al.  The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. , 2018, Inflammatory bowel diseases.

[84]  R. Murray,et al.  The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group , 2018, Journal of psychopharmacology.

[85]  P. McGuire,et al.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. , 2017, The American journal of psychiatry.

[86]  S. O'Sullivan,et al.  A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. , 2017, JCI insight.

[87]  F. Guimarães,et al.  Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life , 2017, Front. Pharmacol..

[88]  G. Gabay,et al.  Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial , 2017, Digestive Diseases and Sciences.

[89]  T. England,et al.  A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol , 2017, Front. Pharmacol..

[90]  Juan Zhou,et al.  Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. , 2017, Clinical hemorheology and microcirculation.

[91]  Jimmy D Bell,et al.  Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study , 2016, Diabetes Care.

[92]  Scott M. Shannon,et al.  Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. , 2015, Integrative medicine.

[93]  R. Mechoulam,et al.  Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[94]  R. Tallarida,et al.  Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice , 2015, Behavioural pharmacology.

[95]  J. Crippa,et al.  Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series , 2014, Journal of clinical pharmacy and therapeutics.

[96]  J. Crippa,et al.  Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial , 2014, Journal of psychopharmacology.

[97]  M. Boks,et al.  Cannabidiol as a potential treatment for psychosis , 2014, European Neuropsychopharmacology.

[98]  Sunjeev K Kamboj,et al.  Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. , 2013, Addictive behaviors.

[99]  A. Zuardi,et al.  Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report , 2013, Journal of clinical pharmacy and therapeutics.

[100]  S. O'Sullivan,et al.  Is the cardiovascular system a therapeutic target for cannabidiol? , 2013, British journal of clinical pharmacology.

[101]  Sunjeev K Kamboj,et al.  Cannabidiol enhances consolidation of explicit fear extinction in humans , 2013, Psychopharmacology.

[102]  M. Hellmich,et al.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.

[103]  Marcos Hortes Nisihara Chagas,et al.  Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients , 2011, Neuropsychopharmacology.

[104]  P. McGuire,et al.  Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report , 2011, Journal of psychopharmacology.

[105]  A. Mechelli,et al.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. , 2010, The international journal of neuropsychopharmacology.

[106]  J. Hallak,et al.  Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). , 2010, Revista brasileira de psiquiatria.

[107]  S. Dursun,et al.  Cannabidiol was ineffective for manic episode of bipolar affective disorder , 2010, Journal of psychopharmacology.

[108]  S. Dursun,et al.  Cannabidiol for the treatment of psychosis in Parkinson’s disease , 2009, Journal of psychopharmacology.

[109]  I. Raz,et al.  Cannabidiol arrests onset of autoimmune diabetes in NOD mice , 2008, Neuropharmacology.

[110]  R. Pertwee,et al.  Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study , 2006, Journal of glaucoma.

[111]  S. Dursun,et al.  Cannabidiol monotherapy for treatment-resistant schizophrenia , 2006, Journal of psychopharmacology.

[112]  P. McGuire,et al.  Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow , 2004, Neuropsychopharmacology.

[113]  F. Guimarães,et al.  Antipsychotic effect of cannabidiol. , 1995, The Journal of clinical psychiatry.

[114]  F. Graeff,et al.  Effects of ipsapirone and cannabidiol on human experimental anxiety , 1993, Journal of psychopharmacology.

[115]  S. Snider,et al.  Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.

[116]  E. Carlini,et al.  Hypnotic and Antiepileptic Effects of Cannabidiol , 1981, Journal of clinical pharmacology.

[117]  E. Carlini,et al.  Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. , 1974, European journal of pharmacology.

[118]  Nicole Lewis,et al.  Cannabidiol in Anxiety and Sleep: A Large Case Series. , 2019, The Permanente journal.

[119]  J. Crippa,et al.  Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report. , 2019, The Permanente journal.

[120]  B. Le Foll,et al.  Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. , 2019, Progress in molecular biology and translational science.

[121]  Scott M. Shannon,et al.  Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. , 2016, The Permanente journal.

[122]  P. McGuire,et al.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. , 2009, Archives of general psychiatry.

[123]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[124]  S. Snider,et al.  Open label evaluation of cannabidiol in dystonic movement disorders. , 1986, The International journal of neuroscience.

[125]  A. Zuardi,et al.  Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. , 1982, Psychopharmacology.